Preserve Access to Affordable Generics and Biosimilars Act

Hozzl · 2025-04-04T13:36:58Z

Explore the details of Senate Bill 1096 Preserve Access to Affordable Generics and Biosimilars Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

4/4/2025, 1:36 PM

Summary of Bill S 1096

Bill 119 s 1096, also known as the "Preserve Access to Affordable Generics and Biosimilars Act," aims to address the issue of brand name drug companies paying generic drug companies to delay the entry of generic drugs into the market. This practice, known as "pay-for-delay," can result in higher drug prices for consumers and limit competition in the pharmaceutical industry.

The bill specifically prohibits brand name drug companies from compensating generic drug companies to delay the entry of generic drugs into the market. Additionally, it also prohibits biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

By preventing these types of agreements, the bill seeks to promote competition in the pharmaceutical industry and increase access to affordable generic and biosimilar drugs for consumers. This legislation is important in ensuring that patients have access to more affordable medication options and that the market remains competitive. Overall, Bill 119 s 1096 aims to protect consumers from potentially harmful practices that can drive up drug prices and limit access to affordable medications. It is a step towards promoting a more competitive and transparent pharmaceutical industry.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1096

Bill S 1096 is currently in the status of Bill Introduced since March 24, 2025. Bill S 1096 was introduced during Congress 119 and was introduced to the Senate on March 24, 2025. Bill S 1096's most recent activity was Committee on the Judiciary. Ordered to be reported without amendment favorably. as of April 3, 2025

Bipartisan Support of Bill S 1096

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1096

Primary Policy Focus

Health

Alternate Title(s) of Bill S 1096

A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Start holding our government accountable!